<i id='FA9CCA3BFA'><strike id='FA9CCA3BFA'><tt id='FA9CCA3BFA'><pre id='FA9CCA3BFA'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Novavax promises a turnaround & Lilly roils the obesity market 
Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder 
Dobbs anniversary: the lost opportunity of abortion as health care 
1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Following judge's order, DOJ releases slightly less 
Medicare proposal to cover medical devices draws a mixed reaction 
4 dead, 2 in stable condition in Philadelphia shooting: Police 
How to save PrEP access — and even expand it 
Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know 
Hepatitis C has a cure — but many Americans still lack access to it
Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
